More About Jay
Jay Rughani is an investing partner at Andreessen Horowitz where he specializes in healthcare technology, with a focus on AI and data products. He is inspired by entrepreneurs using software to accelerate clinical research, enable better care delivery, and increase affordability for patients. Jay helped to lead a16z’s investments in and is partnered with numerous ambitious companies, including Biodock, Freenome, Inductive, Komodo, Midstream, Orchestra, Pearl, Thatch, Thyme, Topography, Turquoise, and Valar.
Prior to joining a16z in 2018, Jay was an early team member at Flatiron Health (acquired by Roche for ~$2B). There, he helped to build some of the company’s first healthcare data & analytics products. He later led numerous commercial partnerships with large biopharma companies, smaller biotechs, and other healthcare organizations. Before Flatiron, he consulted for large healthcare and technology companies around the world at Deloitte, worked at a seed-stage multi-sided network startup called Dealermatch (acquired by Cox Enterprises), and co-founded an unsuccessful startup with his college roommate.
Jay graduated from Emory University with a degree in Mathematics & Economics and grew up mostly in Palm Harbor, FL, apart from a 3 year stint in boarding school in London, UK (not Hogwarts, regrettably).
Latest Content
-
Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.
-
Today, we are thrilled to announce our investment in Alchemy as they work to better connect our life sciences and healthcare delivery systems and solve these supply-demand mismatches in the pharmaceutical value chain. Alchemy has emerged to empower the long tail of independent providers with the physical, clinical, and digital infrastructure they need to fully serve their patient communities effectively, and profitably.
-
This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider to be a good partnership.
-
Tennr understands unstructured inputs, applying AI reasoning and decision-making to perform complex end-to-end workflows.
-
All this to say—it’s time to figure out how to access, pay for, and deliver curative therapies (amongst other high-cost, complex, specialty drugs), at scale. Let’s dive into the specific challenges that need to be surmounted to get this right.
-
100% of stock trades used to be made by humans. Today, 80% are made by computer algorithms. AI is about to bring a similar revolution to healthcare. Over the next few decades, at least half of the $4.3 trillion dollar American healthcare industry will be AI-driven.
-
Our view is that 1) the latest advancements in AI offer a massive enablement opportunity to support our clinicians and 2) this can’t happen without the help of forward-thinking policymakers laying the infrastructure for AI-enabled care.
-
At the end of the day, even the best AI models will fail if they don’t figure out a way to achieve broad distribution and profitable monetization, so it’s important to understand the psyche of the buyers and decision makers who will determine the fate of your products.
-
Building specialist AIs to perform healthcare tasks offers the most challenging technical problems in the field today, as well as the greatest opportunity for impact.
-
The world is amidst an AI-driven industrial revolution. Whether we let it improve the health of Americans is up to how we regulate it. There is no sector where AI can drive more immediate, life-saving impact than in biotechnology and healthcare.
-
How can digital health founders successfully implement channel partnerships to accelerate the distribution of their products and services? When should they use them? How should they use them? We spoke with the founders of Omada, Ginger, and Cedar, each of which have successfully utilized channel partnerships, and surveyed 36 other digital health startups to analyze the state of channel partnerships in the market today.
-
Today’s episode is with Sean Duffy, cofounder and CEO of Omada Health. He is joined by a16z Bio + Health general partner Julie Yoo and investment partner Jay Rughani.
-
The public market situation for healthtech can seem pretty depressing. Recently IPOed healthtech stocks are underperforming the broader market, with some falling 95%+ from their IPO—meanwhile, more traditional companies...
-
The biotech industry’s appetite for science-native SaaS tools is accelerating and will modernize how medicines are discovered, developed, and distributed.
-
“The future is already here - it’s just unevenly distributed,” said science fiction writer William Gibson. As much as we hem and haw about the adoption of value-based care being slow, the fact is that it’s already here in various pockets, and in those pockets, it runs deep.
-
The most significant bottleneck in the adoption of healthcare technology to date has been distribution. Over the last decade, generations of digital health companies have struggled to reach escape velocity—not because th...
-
2021 saw higher than ever funding of startups, continued maturation of the tech-enabled bio and healthcare landscape, and new platforms and business models that propelled growing levels of adoption and scale amongst both...
-
B2C2B — also known as bottom up — has helped companies like Slack, Zoom, Dropbox, and other software companies break into B2B. Now B2C2B is coming to digital health, as a wave of startups are first selling products and s...
-
Welcome to 16 Minutes, our show where we talk about tech trends in the news. We have three expert guests: Eli Van Allen, associate professor of Medicine at Harvard Medical School and chief of the Division of Population Sciences at the Dana-Farber Cancer Institute; a16z bio general partner Vineeta Agarwala; and a16z bio partner Jay Rughani.
-
As new biological technologies shift the way we make new medicines — from “bespoke craftsmanship to industrialized drug development” — we are seeing bio platforms truly deliver a dizzying array of novel discoveries, tool...
-
Healthcare is perhaps unique in that the entire system exists entirely to serve the patient... and yet, in many ways, that same patient is not the customer. In fact, the patient—and the patient's voice—can often be lost...
-
This is episode #2 of our new show, 16 Minutes, where we quickly cover recent headlines of the week, the a16z way -- why they're in the news; why they matter from our vantage point in tech -- and share our experts' views on these trends as well.
